Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06891872
PHASE4

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.

Official title: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine in Healthy Children Aged 18~24 Months: an Open-label, Randomized, Phase Ⅳ Study Clinical Trial

Key Details

Gender

All

Age Range

18 Months - 24 Months

Study Type

INTERVENTIONAL

Enrollment

720

Start Date

2025-05

Completion Date

2025-12

Last Updated

2025-03-24

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Vaicella Vaccine+DTaP on Day 0, MMR on Day 30

Varicella vaccine: lyophilized powder, subcutaneous injection DTaP: intramuscular injection MMR: lyophilized powder, subcutaneous injection

BIOLOGICAL

Varicella vaccine+MMR on Day 0,DTaP on Day 30

Varicella vaccine: lyophilized powder, subcutaneous injection MMR: lyophilized powder, subcutaneous injection DTaP: intramuscular injection

BIOLOGICAL

Varicella Vaccine

lyophilized powder, subcutaneous injection

Locations (1)

Chongqing Center for Disease Control and Prevention

Chongqing, China